Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Marpai’s SEC disclosures often means digging through dense healthcare regulations, AI R&D costs, and dozens of reimbursement tables. Locating Marpai insider trading Form 4 transactions or the latest technology spend hidden in a 300-page 10-K can consume hours.
Stock Titan solves that overwhelm. Our AI reads every Marpai quarterly earnings report 10-Q filing, flags margin shifts inside the benefits administration segment, and delivers plain-English highlights in seconds. Need real-time alerts? We stream Marpai Form 4 insider transactions real-time so you see executive moves before markets react. From Marpai 8-K material events explained to a Marpai proxy statement executive compensation breakdown, each document is summarized, linked, and searchable.
What you’ll uncover with one click:
- Cash burn, client count, and AI platform investment pulled from the Marpai annual report 10-K simplified.
- Quarter-over-quarter claims volume trends drawn from earnings data and presented as visual dashboards.
- Automated red-flag alerts on related-party deals, insider gifts, and Marpai executive stock transactions Form 4.
Whether you’re comparing cost-containment efficiency, monitoring Marpai earnings report filing analysis, or simply understanding Marpai SEC documents with AI, our platform delivers every filing type the moment EDGAR releases it—no jargon, no delay, just actionable clarity.
Marpai, Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors to raise approximately $350,000 in a private placement. The Company agreed to issue and sell 350,000 shares of Class A common stock together with warrants to purchase up to 700,000 additional shares of common stock, at a combined purchase price of $1.00 per share and accompanying warrant.
The common warrants have an exercise price of $1.00 per share, are exercisable immediately after closing, and remain exercisable for three years from issuance, with customary anti-dilution provisions. Marpai plans to use the proceeds for working capital and general corporate purposes, and granted investors a six‑month right to include the shares and warrant shares in any other registration of securities it files, subject to limited exceptions.
Marpai, Inc. reported Q3 results and flagged substantial doubt about its ability to continue as a going concern. Revenue was $4.037 million, down 42% year over year, as customer turnover reduced volumes. The quarter’s net loss was $3.494 million, with interest expense of $797 thousand reflecting higher-cost debt.
At September 30, 2025, cash and cash equivalents were $445 thousand against total liabilities of $46.099 million and a stockholders’ deficit of $33.346 million. Working capital was negative $10.7 million. Convertible debentures had a net carrying amount of $9.840 million bearing 14% interest with $250 thousand monthly principal payments; liabilities due to AXA totaled $18.952 million due by December 31, 2028.
Year to date, revenue was $14.111 million (down 34.6%) and operating loss improved to $8.627 million due to cost reductions across G&A, facilities, and depreciation. Management is exploring strategic alternatives and raised capital through several private placements. The company disclosed ongoing litigation relating to a lease subtenant dispute.
Marpai, Inc. (MRAI) filed a current report announcing it issued a press release with selected financial information for the three and nine months ended September 30, 2025. The release is provided as Exhibit 99.1.
The filing identifies the company’s Class A common stock trading on the OTCQX Market under the symbol MRAI. No additional operational or financial details are included in this report beyond the exhibit reference.
Marpai, Inc. (MRAI) director purchase disclosed. A director reported buying 100,000 shares of Class A common stock at $1.00 per share in a private placement on November 7, 2025, and received common warrants to purchase up to 200,000 additional shares at an exercise price of $1.00.
The warrants are exercisable immediately and remain exercisable until November 6, 2028. Following the transaction, the director directly owns 1,089,073 shares.
Marpai (MRAI) reported an insider transaction by a director. On 11/07/2025, the reporting person purchased 50,000 shares of Class A common stock at $1.00 per share and acquired common warrants for up to 100,000 shares with a $1.00 exercise price. The warrants are exercisable immediately and expire on 11/06/2028. Following the transaction, the insider beneficially owned 272,000 shares, held directly.
Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares. The warrants are exercisable immediately at $1.00 per share and remain exercisable for three years from the 11/07/2025 issuance date, expiring on 11/06/2028.
The securities are held indirectly by the Dallas S. Scrip and Michelle R. Script Trust, for which the reporting person and spouse serve as co‑trustees with shared voting and investment control.
Marpai, Inc. (MRAI) reported an insider purchase by director Robert Pons. On November 7, 2025, he bought 50,000 shares of Class A common stock in a private placement at $1.00 per share, together with common warrants to purchase up to 100,000 shares at an exercise price of $1.00.
The warrants are exercisable immediately and expire on November 6, 2028. Following the transaction, Pons beneficially owned 359,200 shares directly.
Marpai, Inc. entered a Securities Purchase Agreement for a private placement of 3,850,000 shares of Class A common stock and warrants to purchase up to 7,700,000 shares, priced at $1.00 per share with an accompanying warrant.
The offering is expected to generate approximately $4 million in gross proceeds for working capital and general corporate purposes. Warrants are exercisable immediately at $1.00 per share and have a three‑year term, with customary anti‑dilution provisions. Participants include the Company’s COO and President, the Board’s chairman, and certain directors.
The securities are being issued under Section 4(a)(2) and/or Rule 506(b) of Regulation D, and may not be sold in the U.S. absent registration or an exemption. Purchasers have a six‑month right to include the common and warrant shares in any registration the Company files (other than Rule 145(a) transactions). Closing is expected on or about November 7, 2025, subject to customary conditions.
Marpai, Inc. (MRAI) CEO, Director, and 10% Owner Damien Lamendola reported acquiring 550,000 shares of Class A Common Stock on 10/20/2025 at $0, reflecting vested RSUs.
Following the transaction, he reported 1,350,000 shares held directly and indirect holdings of 6,419,893 shares through HillCour Investment Fund, LLC and 931,674 shares through WellEnterprises USA, LLC, as disclosed in footnotes.
Marpai, Inc. (MRAI) reported an insider equity award. A director acquired 75,000 Class A common shares on 10/20/2025 with a transaction code “A,” indicating an award or grant. The filing notes the shares came from RSUs that were deemed fully vested on the issuance date.
The reported acquisition price was $0.00. Following this transaction, the reporting person beneficially owns 222,000 shares, held directly. This filing records an equity compensation event and updates the insider’s holdings.
FAQ
What is the current stock price of Marpai (MRAI)?
What is the market cap of Marpai (MRAI)?
